Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.verified

ACOR

Price:

$0.661

Market Cap:

$821.03K

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the deve...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2006-02-10

Stock Exchange

NASDAQ

Ticker

ACOR

The ROE as of November 2024 (TTM) for Acorda Therapeutics, Inc. (ACOR) is 485.80%

According to Acorda Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 485.80%. This represents a change of 1.47% compared to the average of 30.93% of the last 4 quarters.

Acorda Therapeutics, Inc. (ACOR) Historical ROE (quarterly & annually)

How has ACOR ROE performed in the past?

The mean historical ROE of Acorda Therapeutics, Inc. over the last ten years is -14.64%. The current 485.80% ROE has changed -3417.80% with respect to the historical average. Over the past ten years (40 quarters), ACOR's ROE was at its highest in in the December 2023 quarter at 137.86%. The ROE was at its lowest in in the September 2019 quarter at -93.67%.

Quarterly (TTM)
Annual

Average

-14.64%

Median

-23.57%

Minimum

-87.82%

Maximum

160.08%

Acorda Therapeutics, Inc. (ACOR) ROE by Quarter and Year

Discovering the peaks and valleys of Acorda Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 711.88%

Maximum Annual ROE = 160.08%

Minimum Annual Increase = -1695.66%

Minimum Annual ROE = -87.82%

Quarterly (TTM)
Annual
YearROEChange
2023160.08%-327.36%
2022-70.41%2.36%
2021-68.78%64.34%
2020-41.85%-52.34%
2019-87.82%-1695.66%
20185.50%-112.81%
2017-42.95%711.88%
2016-5.29%-388.52%
20151.83%-43.94%
20143.27%-12.39%

Acorda Therapeutics, Inc. (ACOR) Average ROE

How has ACOR ROE performed in the past?

The current ROE of Acorda Therapeutics, Inc. (ACOR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

6.96%

5-year avg

-21.76%

10-year avg

-14.64%

Acorda Therapeutics, Inc. (ACOR) ROE vs. Peers

How is ACOR’s ROE compared to its peers?

Acorda Therapeutics, Inc.’s ROE is greater than Taisho Pharmaceutical Holdings Co., Ltd. (1.26%), less than Shionogi & Co., Ltd. (12.38%), greater than Vivesto AB (-83.88%), greater than Pacira BioSciences, Inc. (-10.70%), greater than Sunshine Biopharma, Inc. (-17.88%), greater than Lucy Scientific Discovery Inc. (-296.96%), greater than Biofrontera Inc. (-324.62%), greater than Jupiter Wellness, Inc. (-5.81%), greater than Shuttle Pharmaceuticals Holdings, Inc. (-582.98%), less than Lifecore Biomedical, Inc. (17.23%), greater than Journey Medical Corporation (-132.10%), greater than Akanda Corp. (-753.35%), greater than China Pharma Holdings, Inc. (-63.93%), greater than Universe Pharmaceuticals INC (-55.97%), greater than Sonoma Pharmaceuticals, Inc. (-63.67%), greater than Petros Pharmaceuticals, Inc. (-122.55%), greater than Evoke Pharma, Inc. (-308.51%), greater than Cumberland Pharmaceuticals Inc. (-40.17%), less than Agile Therapeutics, Inc. (104.04%), greater than PainReform Ltd. (-450.64%),

Build a custom stock screener for Acorda Therapeutics, Inc. (ACOR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Acorda Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Acorda Therapeutics, Inc. (ACOR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Acorda Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Acorda Therapeutics, Inc.'s ROE?

How is the ROE calculated for Acorda Therapeutics, Inc. (ACOR)?

What is the highest ROE for Acorda Therapeutics, Inc. (ACOR)?

What is the 3-year average ROE for Acorda Therapeutics, Inc. (ACOR)?

What is the 5-year average ROE for Acorda Therapeutics, Inc. (ACOR)?

How does the current ROE for Acorda Therapeutics, Inc. (ACOR) compare to its historical average?